Preface |
|
xiii | |
|
1 Metallodrugs in Medicine: Present, Past, and Future Prospects |
|
|
1 | (40) |
|
|
|
|
2 | (4) |
|
1.2 Therapeutic Metallodrugs |
|
|
6 | (17) |
|
1.2.1 Anticancer Metallodrugs |
|
|
6 | (1) |
|
1.2.1.1 Mechanism of Anticancer Action |
|
|
7 | (8) |
|
1.2.2 Antimicrobial and Antiviral Metallodrugs |
|
|
15 | (1) |
|
1.2.2.1 Antimicrobial Metallodrugs |
|
|
15 | (1) |
|
1.2.2.2 Antiviral Metallodrugs |
|
|
16 | (1) |
|
1.2.3 Radiopharmaceuticals and Radiodiagnostic Metallodrugs |
|
|
17 | (2) |
|
1.2.4 Anti-Diabetic Metallodrugs |
|
|
19 | (3) |
|
1.2.5 Catalytic Metallodrugs |
|
|
22 | (1) |
|
|
23 | (2) |
|
|
25 | (16) |
|
|
26 | (15) |
|
2 Chemotherapeutic Potential of Ruthenium Metal Complexes Incorporating Schiff Bases |
|
|
41 | (30) |
|
|
|
|
|
|
|
|
42 | (1) |
|
2.2 Schiff Base Complexes of Ruthenium as Anticancer Agents |
|
|
43 | (20) |
|
|
63 | (8) |
|
|
64 | (7) |
|
3 Role of Metallodrugs in Medicinal Inorganic Chemistry |
|
|
71 | (44) |
|
|
|
|
|
|
72 | (2) |
|
3.2 Platinum Anticancer Drugs |
|
|
74 | (8) |
|
3.2.1 Nucleophilic Displacement Reactions in Complexes of Platinum |
|
|
80 | (1) |
|
3.2.2 Mode of the Interaction of Cisplatin Species With Nitrogen Donors of DNA Strand |
|
|
80 | (2) |
|
3.2.3 Systemic Toxicity of Cisplatin |
|
|
82 | (1) |
|
3.3 Copper-Based Anticancer Complexes |
|
|
82 | (7) |
|
3.3.1 Copper is Essential for Health and Nutrition |
|
|
82 | (1) |
|
3.3.2 Healthcare Applications of Copper |
|
|
83 | (1) |
|
3.3.3 Copper and Human Health Disorders |
|
|
83 | (1) |
|
3.3.3.1 Wilsons Disease (WD) |
|
|
84 | (1) |
|
|
85 | (1) |
|
3.3.4 Role of Copper Complexes as Potential Therapeutic Agents |
|
|
85 | (1) |
|
3.3.4.1 Thiosemicarbazones-Based Complexes |
|
|
86 | (2) |
|
3.3.4.2 Quinolones-Based Copper Complexes |
|
|
88 | (1) |
|
|
88 | (1) |
|
3.4 Zinc Anticancer Complexes |
|
|
89 | (14) |
|
3.4.1 Biologically Importance of Zinc |
|
|
90 | (2) |
|
3.4.2 Schiff Base Chemistry |
|
|
92 | (1) |
|
3.4.2.1 Schiff Base and Their Metal Complexes |
|
|
92 | (1) |
|
3.4.3 Zinc-Based Complexes |
|
|
93 | (1) |
|
3.4.4 Top Food Sources of Zinc |
|
|
94 | (3) |
|
3.4.5 Role of Zinc in Human Body |
|
|
97 | (1) |
|
3.4.6 Zinc as a Health Benefit |
|
|
98 | (2) |
|
3.4.7 Zinc in Alloy and Composites |
|
|
100 | (1) |
|
3.4.8 Zinc Supplementation as a Treatment |
|
|
100 | (1) |
|
|
101 | (1) |
|
|
102 | (1) |
|
3.4.8.3 Zinc and Viral Infections |
|
|
102 | (1) |
|
3.4.9 Gastrointestinal Effects |
|
|
103 | (1) |
|
3.5 Future Prospects of Metallodrugs |
|
|
103 | (12) |
|
|
104 | (11) |
|
4 Ferrocene-Based Metallodrugs |
|
|
115 | (22) |
|
|
|
|
|
115 | (2) |
|
4.2 Ferrocene-Based Antimalarial Agents |
|
|
117 | (1) |
|
4.2.1 Mechanism of Action |
|
|
118 | (1) |
|
4.3 Ferrocene-Based Antibacterial and Antifungal Drugs |
|
|
118 | (5) |
|
4.3.1 Schiff Base Derived Ferrocene Conjugates as Antibacterial Agents |
|
|
119 | (2) |
|
4.3.2 Ferrocenyl Guanidines as Antibacterial and Antifungal Agents |
|
|
121 | (1) |
|
4.3.3 Sedaxicene as Antifungal Agents |
|
|
122 | (1) |
|
4.4 Ferrocene-Based Anti-Tumor and Anti-Cancerous Drugs |
|
|
123 | (8) |
|
4.4.1 Ferricenium Salts as Anti-Tumor Agents |
|
|
124 | (1) |
|
4.4.2 Ferrocenylalkylazoles Active Anti-Tumor Drugs |
|
|
124 | (1) |
|
4.4.3 Ferrocene Conjugated to Peptides for Lung Cancer |
|
|
125 | (1) |
|
4.4.4 Ferrocenylalkyl Nucleobases Potential Anti-Cancerous Drugs |
|
|
126 | (1) |
|
4.4.5 Ferrocenyl Sub-Ordinates of Illudin-M |
|
|
126 | (1) |
|
4.4.6 Ferrocenyl Derivatives of Retinoids Potential Anti-Tumor Drug |
|
|
127 | (1) |
|
4.4.7 Targeting Breast Cancer With Selective Ferrocene-Based Estrogen Receptor Modulators (SERM) |
|
|
128 | (3) |
|
|
131 | (1) |
|
4.6 Future of Ferrocene-Based Drugs |
|
|
131 | (6) |
|
|
132 | (5) |
|
5 Recent Advances in Cobalt Derived Complexes as Potential Therapeutic Agents |
|
|
137 | (20) |
|
|
|
|
|
137 | (1) |
|
5.2 Cobalt Complexes as Potential Therapeutic Agents |
|
|
138 | (15) |
|
|
153 | (4) |
|
|
154 | (3) |
|
6 NO-, CO-, and H2S-Based Metallopharmaceuticals |
|
|
157 | (46) |
|
|
|
|
158 | (2) |
|
6.2 Signaling Molecules: Concept of "Gasotransmitter" |
|
|
160 | (7) |
|
6.2.1 Therapeutic Applications of NO, CO, and H2S |
|
|
162 | (1) |
|
6.2.1.1 Exogenous NO Donating Molecules |
|
|
163 | (4) |
|
6.3 NO Donors Incorporated in Polymeric Matrices |
|
|
167 | (3) |
|
6.3.1 Metal Nitrosyl Complexes |
|
|
168 | (1) |
|
6.3.1.1 Sodium Nitroprusside (SNP) |
|
|
168 | (2) |
|
6.4 Dinitrosyl Iron Thiol Complexes (DNICs) |
|
|
170 | (1) |
|
6.5 Photoactive Transition Metal Nitrosyls as NO Donors |
|
|
170 | (3) |
|
6.6 Exogenous CO Donating Molecules |
|
|
173 | (3) |
|
6.7 H2S Donating Compounds |
|
|
176 | (9) |
|
6.7.1 H2S Gas: A Fast Delivering Compound |
|
|
176 | (1) |
|
6.7.2 Sulfide Salts: Fast Delivering H2S Compounds |
|
|
177 | (1) |
|
|
178 | (1) |
|
6.7.3.1 Slow-Delivering H2S Compounds |
|
|
178 | (1) |
|
6.7.3.2 H2S-Releasing Composite Compounds |
|
|
179 | (3) |
|
6.7.4 Naturally Occurring Plant Derived Compounds |
|
|
182 | (1) |
|
|
182 | (2) |
|
6.7.4.2 Broccoli and Other Cruciferous Vegetables |
|
|
184 | (1) |
|
6.8 Concluding Remarks and Future Outlook |
|
|
185 | (18) |
|
|
186 | (17) |
|
7 Platinum Complexes in Medicine and in the Treatment of Cancer |
|
|
203 | (44) |
|
|
|
|
203 | (6) |
|
7.1.1 Characteristic Features of Cancer Cells |
|
|
205 | (1) |
|
7.1.2 Definition of Anticancer Compound |
|
|
206 | (1) |
|
7.1.3 Anticancer Attributes of Pt Complexes |
|
|
207 | (1) |
|
7.1.4 Native State Behavior of Pt Complexes |
|
|
208 | (1) |
|
7.2 Compatibility of Pt Compounds in Cancer Treatment |
|
|
209 | (5) |
|
7.2.1 Significance of DNA as Primary Target |
|
|
209 | (1) |
|
7.2.2 Kinetics of DNA Binding Activities |
|
|
210 | (1) |
|
7.2.3 Structural and Regioselectivity of DNA Adducts |
|
|
210 | (1) |
|
7.2.4 Studies on Action Mechanism |
|
|
211 | (3) |
|
7.3 Pt Complexes as Anticancer Drugs |
|
|
214 | (17) |
|
7.3.1 DNA-Coordinating Pt(II) Complexes |
|
|
214 | (5) |
|
7.3.2 DNA-Covalently Binding Pt(II) Complexes |
|
|
219 | (3) |
|
7.3.3 Targeted Pt(II) Complexes |
|
|
222 | (2) |
|
|
224 | (1) |
|
7.3.5 Multiple Action of Pt(IV) Prodrugs |
|
|
225 | (3) |
|
7.3.6 Targeted Pt(IV) Prodrugs |
|
|
228 | (3) |
|
7.3.7 Photodynamic Killing of Cancer Cell by Pt Complexes |
|
|
231 | (1) |
|
|
231 | (16) |
|
|
232 | (1) |
|
|
232 | (15) |
|
8 Recent Advances in Gold Complexes as Anticancer Agents |
|
|
247 | (26) |
|
|
|
|
|
|
|
248 | (2) |
|
8.2 Evolution of Metal Complexes as Anticancer Agents |
|
|
250 | (1) |
|
|
251 | (11) |
|
8.3.1 Complexes with Nitrogen Donar Ligands |
|
|
252 | (2) |
|
8.3.2 Complexes with Sulphur Donar Ligands |
|
|
254 | (1) |
|
8.3.3 Complexes with Phosphorus Donar Ligands |
|
|
255 | (1) |
|
8.3.4 Complexes with Sulphur-Phosphorus Donar Ligands |
|
|
256 | (3) |
|
8.3.5 Organometallic Gold Complexes |
|
|
259 | (1) |
|
|
260 | (2) |
|
8.4 Nano-Formulations of Gold Complexes |
|
|
262 | (1) |
|
8.5 Future Challenges and Perspectives |
|
|
263 | (2) |
|
|
265 | (8) |
|
|
266 | (1) |
|
|
266 | (7) |
|
9 Recent Developments in Small Molecular HIV-1 and Hepatitis B Virus RNase H Inhibitors |
|
|
273 | (20) |
|
|
|
|
|
|
|
273 | (3) |
|
9.1.1 Activity and Function of HIV and HBV RNases H |
|
|
274 | (1) |
|
9.1.2 The Metal-Chelating RNase H Active Site |
|
|
274 | (2) |
|
9.2 RNase H Inhibitors and Strategies in the Discovery of Active Compounds |
|
|
276 | (10) |
|
9.2.1 High-Throughput Screening |
|
|
276 | (2) |
|
9.2.2 Design Based on Pharmacophore Models |
|
|
278 | (1) |
|
9.2.3 Novel Inhibitors Obtained by Using "Click Chemistry" |
|
|
279 | (1) |
|
9.2.4 Dual-Target Inhibitors Against HIV-1 Integrase (IN) and RNase H |
|
|
280 | (2) |
|
9.2.5 Inhibitors Obtained by Using Privileged Fragment-Based Libraries |
|
|
282 | (1) |
|
9.2.6 RNase H Inhibitors in Natural Products |
|
|
283 | (1) |
|
9.2.7 Drug Repurposing Based on Privileged Structures |
|
|
284 | (2) |
|
|
286 | (7) |
|
|
287 | (6) |
|
10 The Role of Metals and Metallodrugs in the Modulation of Angiogenesis |
|
|
293 | (26) |
|
|
|
|
294 | (3) |
|
10.2 Metallodrugs in Anticancer Therapy |
|
|
297 | (3) |
|
10.3 Angiogenesis as a Substantial Target of Tumorigenesis |
|
|
300 | (2) |
|
10.4 Metals and Metallodrugs in Angiogenesis |
|
|
302 | (4) |
|
10.5 Concluding Remarks and Future Prospects |
|
|
306 | (13) |
|
|
306 | (13) |
|
11 Metal-Based Cellulose: An Attractive Approach Towards Biomedicine Applications |
|
|
319 | (44) |
|
|
|
|
320 | (1) |
|
11.2 History of Cellulose |
|
|
320 | (1) |
|
11.3 The Properties and Structure of Cellulose |
|
|
321 | (1) |
|
11.4 Modification of Cellulose |
|
|
322 | (22) |
|
|
322 | (2) |
|
|
324 | (2) |
|
|
326 | (5) |
|
|
331 | (2) |
|
|
333 | (3) |
|
|
336 | (3) |
|
11.4.7 Nucleophilic Substitution |
|
|
339 | (2) |
|
11.4.8 Further Modification |
|
|
341 | (3) |
|
11.5 Present and Future Medical Applications of Cellulose as Well as Its Components |
|
|
344 | (7) |
|
11.5.1 Cellulose Used as Wound Dressing |
|
|
344 | (1) |
|
11.5.2 Dental Applications |
|
|
345 | (1) |
|
|
346 | (2) |
|
11.5.4 Controllable Drug Delivery System |
|
|
348 | (1) |
|
11.5.5 Blood Purification |
|
|
348 | (2) |
|
|
350 | (1) |
|
|
351 | (1) |
|
|
351 | (12) |
|
|
352 | (11) |
|
12 Multifunctional Nanomedicine |
|
|
363 | (40) |
|
|
|
|
|
364 | (2) |
|
12.2 Diagnostics and Imaging |
|
|
366 | (3) |
|
12.3 Drug Delivery and Therapy |
|
|
369 | (16) |
|
12.3.1 Drug Delivery by Organic Nanomaterials |
|
|
369 | (1) |
|
12.3.1.1 Liposomal Drug Delivery |
|
|
369 | (2) |
|
12.3.1.2 Polymeric Drug Delivery |
|
|
371 | (2) |
|
12.3.1.3 Proteins and Peptides for Drug Delivery |
|
|
373 | (1) |
|
12.3.2 Drug Delivery by Inorganic Nanomaterials |
|
|
374 | (1) |
|
12.3.2.1 Metal and Metal Oxides |
|
|
374 | (1) |
|
|
375 | (1) |
|
12.3.2.3 Carbon-Based NPs |
|
|
375 | (3) |
|
12.3.2.4 Silicon-Based Nanostructures for Drug Delivery |
|
|
378 | (1) |
|
|
379 | (1) |
|
12.3.3.1 Photodynamic Therapy |
|
|
380 | (1) |
|
12.3.3.2 Photothermal Therapy |
|
|
381 | (2) |
|
|
383 | (1) |
|
12.3.5 Neutron Capture Therapy |
|
|
384 | (1) |
|
12.4 Regenerative Medicine |
|
|
385 | (1) |
|
12.5 Future Prospects and Conclusion |
|
|
386 | (17) |
|
|
387 | (16) |
Index |
|
403 | |